Neuralink rival gets FDA approval for brain implant device

Paradromics-Cortical-greenprophet.jpg

The Connect-One Study will initially enroll two participants—with impaired speech and limited extremity movement (upper and lower) due to severe loss of voluntary motor control—who live within four hours of three clinical sites, UC Davis in Sacramento, Massachusetts General Hospital in Boston, and Harvard Medical School.‍University of Michigan in Ann Arbor, MI - led by Investigator Matthew Willsey, M.D., Ph.D., a neurosurgeon with dual faculty appointments in Neurosurgery and Biomedical Engineering. 

Read more